Valeant Pharma (VRX) Results Suggest Disruption in the Business - Evecore ISI's Raffat

Deutsche Bank Comments on Valeant Pharma (VRX) Following Q4 Call

Deutsche Bank analyst Gregg Gilbert commented on Valeant Pharma (NYSE: VRX) after it released Q4 earnings and discussed challenges on its conference call. The analyst noted operational challenges and overhang from its 10-K delay.

"The new 2016 guidance reflects in large part lower growth assumptions for the core US business (including Dermatology and GI) without offsetting cost reductions (which the company will explore). On the positive side, VRX described making progress with payors, and cited greater visibility on managed... More

UPDATE: Piper Jaffray Downgrades Valeant Pharmaceuticals (VRX) to Underweight

(Updated - March 15, 2016 11:20 AM EDT)

Piper Jaffray downgraded Valeant Pharmaceuticals (NYSE: VRX) from Neutral to Underweight. Analyst David Amsellem called Valeant a "broken company" and noted trouble spots across a number of segments.

Amsellem explained the downgrade, "VRX reported 4Q15 adjusted... More

Valeant Pharma (VRX) Conference Call Ends

Valeant Pharma (NYSE: VRX) brutal conference call ends. With shares down 36.7% traders will be looking for the stock to possibly rally later in the session.

Horizon Pharma (HZNP) Falls Amid Lower Outlook from Valeant

Horizon Pharma (NASDAQ: HZNP) is seeing morning pressure following weak earnings and lower guidance from peer Valeant Pharma (NYSE: VRX). HZNP is down 7% while VRX is down 31.6%.

Valeant Pharma (VRX) CEO said his best estimate is 10-K will be filed in April - Bloomberg

Valeant Pharma (NYSE: VRX) CEO said his best estimate is 10-K will be filed in April - Bloomberg

Valeant Pharma (VRX) Corrects adj.-EBITDA Guidance Lower to ~$6B on Call

Valeant Pharma (NYSE: VRX) corrected EBITDA guidance for the next four quarters to about $6 billion on its earning call. An earlier release forecast next four quarters (second quarter 2016 first quarter 2017) guidance of about $6.2 - $6.6 billion.

Shares are lower by 36 percent.

Pre-Open Stock Movers 03/15: (CPXX) (SZYM) (ESI) Higher; (VRX) (LINE) (DDD) Lower (more...)

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) 409.5% HIGHER; announced positive results from the Phase 3 trial of VYXEOS (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.

Solazyme, Inc. (Nasdaq: SZYM) 37.9% HIGHER; has signed a... More

Valeant Pharma (VRX) Misses Dramatically Reduced Expectations - BMO

BMO Capital analyst, Alex Arfaei, posted an earnings flash on Valeant Pharmaceuticals' (NYSE: VRX) miss and guide down. The call is ongoing and began at 8:00AM.

This morning, Valeant reported unaudited 4Q15 revenues of $2.78B, 1% above consensus of $2.75B. Gross margin of 75.6%... More

The Single Most Important Catalyst for Valeant Pharma (VRX) Near-Term...

Valeant Pharma (NYSE: VRX) is down 15% after posting unaudited fourth quarter result and disappointing 2016 guidance. However, according to Evecore ISI analyst Umer Raffat, the single most important catalyst for Valeant near-term is timing for covenants/10-K filing to avoid default .

The all-important date of a default is March 30th + 30 days, so April 29.

Covenant... More

Drugmaker Valeant faces debt default risk; shares plunge 50 percent

By Rod Nickel and Caroline Humer

(Reuters) - Valeant Pharmaceuticals International Inc's (NYSE: VRX) shares plunged 50 percent on Tuesday after the company said a delay in filing its annual report put it in danger of a default on its $30 billion in debt.

The news from the Canadian drugmaker, which also slashed its 2016 sales and earnings outlook, prompted Bill Ackman, whose Pershing Square Capital Management is one of Valeant's largest shareholders, to tell investors that he would take a much more active role there.

For years, Valeant was an investor darling, buying... More

Valeant Pharma (VRX) Won't File 10-K Within 15-Day Extension Period

Valeant Pharma (NYSE: VRX) disclosed the following on Tuesday:

Item 2.02 Results of Operations and Financial Condition

On March 15, 2016, Valeant Pharmaceuticals International, Inc. (the Company) issued a press release announcing preliminary unaudited financial results for the fourth quarter ended December 31, 2015. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

The fourth quarter 2015 results are preliminary because, as previously announced, the Company has delayed the filing of its Annual Report on Form 10-K for the year ended December 31, 2015 pending completion of the Companys... More

Valeant Pharma (VRX) Misses Q4 EPS by 11c; Cuts Q1, FY16 Outlook

Valeant Pharma (NYSE: VRX) reported Q4 EPS of $2.50, $0.11 worse than the analyst estimate of $2.61. Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.75 billion.

GUIDANCE:

Valeant Pharma sees Q1 2016 EPS of $1.30 - $1.55, versus prior guidance of $2.35 - $2.55 and the consensus of $2.63. Valeant Pharma sees Q1 2016 revenue of $2.3 - $2.4 billion, versus prior guidance of $2.8 - $3.1 billion and the consensus of $2.82 billion.

Valeant Pharma sees FY2016 EPS... More